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Abstract To address the effect of an agglutogen on virus
infection, we studied the avidin-associated inhibition of infection
by biotinylated M13 phages (BIO-phages). Microscopic obser-
vation of mixtures of BIO-phages and avidin^fluorescein
conjugates revealed many aggregates. Even at low phage
concentrations, avidin induced inhibition of infection signifi-
cantly. Anti-M13 phage antibody also made aggregates and
inhibited the infection but in a different manner from avidin. The
inhibition by avidin was at v2 Wg/ml, time dependent and
marked until 10 min after the mixing of the BIO-phages and
Escherichia coli. On the other hand, antibody inhibited the
infection at v0.1 Wg/ml dose dependently, and the inhibition
was time dependent and marked until 45 min after the mixing at
moderate and low phage concentrations. These results indicate
that avidin against BIO-phages and antibodies are agglutogens,
and the inhibition of the BIO-phages by avidin is closely related
to the tetramerization of avidin. Agglutogens may be novel
alternative antiviral drugs. . 2002 Published by Elsevier Sci-
ence B.V. on behalf of the Federation of European Biochemical
Societies.
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1. Introduction
Developing e¡ective antiviral drugs is an intriguing chal-
lenge for many researchers, especially from therapeutic view-
points. For example, combination drug therapy against hu-
man immunode¢ciency virus-1 (HIV-1) targets two virus-
speci¢c enzymes, HIV-1 protease and reverse transcriptase
[1]. In a new strategy, peptide and protein inhibitors that
target the gp41 coiled-coil pocket have been developed to
inhibit HIV entry [2^4]. A recombinant immunotoxin directed
against the HIV-1 envelope glycoprotein has been developed
to kill infected cells speci¢cally [5^7]. However, these drugs all
target virus-infected cells or factors required for virus entry,
not the virus itself. Agglutogens may be candidate antiviral
agents for direct inhibition of the virus.
To address the e¡ects of agglutogens on virus infection, we
prepared biotinylated ¢lamentous bacteriophages (BIO-
phages) [8] and investigated the in£uence of avidin on their
infection of Escherichia coli. We found that avidin connected
the BIO-phages to each other, causing aggregation and lead-
ing to a strong inhibition of infection. In addition, we discuss
the characteristics and mechanisms of this inhibition and de-
scribe the potential use of agglutogens as virus inhibitors.
2. Materials and methods
2.1. Materials
D-Biotin-N-hydroxysuccinimide ester (BIO) was purchased from
Roche Molecular Biochemicals (Tokyo, Japan), avidin^horseradish
peroxidase conjugate (avidin^HRP) from ProZyme (San Leandro,
CA, USA), £uorescein avidin D from Vector Laboratories (Burlin-
game, CA, USA), and avidin from Wako Fine Chemicals Inc. (Osaka,
Japan). Anti-M13 monoclonal antibody was purchased from Amer-
sham Pharmacia Biotech UK Ltd. (Buckinghamshire, UK). This anti-
body is a subclass IgG2a mouse monoclonal antibody puri¢ed from
BALB/c mouse ascites £uid and reacts speci¢cally with the bacterio-
phage M13 major coat protein product of gene VIII. All other re-
agents were of biochemical research grade.
2.2. Assessment of the ability of avidin to bind BIO-phages
BIO-phages were prepared as described [8]. BIO-phages were de-
tected by using quantitative dot blotting as described previously [8,9]
with some modi¢cation. Aliquots of BIO-phages and avidin^HRP
were bound to polyvinyldi£uoride membranes. The membranes were
washed once in phosphate-bu¡ered saline (PBS), blocked with PBS
containing 2% skim milk, and incubated with 2000-fold diluted avi-
din^HRP for 60 min at room temperature. After washing with PBS
containing 0.1% Tween-20, the blots were developed by using a chem-
iluminescent substrate and analyzed by using a luminescent image
analyzer LAS-1000 (Fuji Photo Film, Tokyo, Japan).
2.3. Confocal microscopy
We mixed 5 Wl of BIO-phages (6.0U107 cfu) or M13KO7 phages
(2.2U107 cfu) with 5 Wl of £uorescein avidin D (0 to 1 mg/ml in PBS)
at room temperature. Just after the mixing, the mixtures were
mounted on glass slides, covered with cover glasses, and viewed
through a confocal laser scanning microscope (Leica TCS NT, Hei-
delberg, Germany). To observe the antibody-associated inhibition,
M13KO7 phages (8.0U107 cfu/Wl) and anti-M13 antibody^£uorescein
conjugate (1 mg/ml) were used instead of BIO-phages and avidin,
respectively.
2.4. Assays of inhibition of phage infection
E. coli JM109 cells were grown at 37‡C overnight in LB medium.
We combined 490 Wl of the overnight culture with 5 Wl of an avidin
solution (0^1 mg/ml in PBS) and then added 5 Wl of a solution con-
taining BIO-phages (7U100, 9U100, 2.3U101, 4.5U101, 1.2U102,
2.8U102, 7.5U102, 5.3U103, 1.6U105, 4.3U106 cfu/Wl) or unlabeled
M13KO7 phages (1.5U106 cfu/Wl). The reaction mixture was incu-
bated for 1 h at 37‡C, after which it was plated and incubated over-
night, and the bacterial colonies were counted. The data are presented
as the meansL 1 standard deviation from three experiments. To assess
the antibody-associated inhibition of infection, 5 Wl anti-M13 anti-
body (0^1 mg/ml in PBS) and 5 Wl of M13KO7 phages (2.3U101,
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6.1U102, 3.0U104, 7.4U105, 1.0U107 cfu/Wl) were used instead of
avidin and BIO-phages, respectively.
We assessed the time-dependency of the avidin-associated inhibition
of infection. At time 0, 490 Wl of the overnight cultured E. coli JM109
cells solution and 5 Wl of BIO-phages (1.2U102, 6.3U104, 3.2U106
cfu/Wl) were combined and incubated at 37‡C. After various times, 5 Wl
avidin (1 mg/ml) was added to the culture solutions, which were then
incubated at 37‡C until 1 h after the start of the assay. After incuba-
tion it was plated and incubated overnight, and the bacterial colonies
were counted. The data are presented as the meansL1 standard de-
viation from three experiments. To assess the time-dependency of the
antibody-associated inhibition, 5 Wl of M13KO7 phages (2.4U102,
5.2U104, 2.1U106 cfu/Wl) and 5 Wl of anti-M13 (1 mg/ml in PBS)
were used instead of BIO-phages and avidin, respectively.
3. Results
3.1. Assessment of the binding of BIO-phages and avidin
To assess their ability to bind to avidin, BIO-phages and
avidin^HRP were blotted on membranes and reacted with
avidin^HRP. The peroxidase activities of the directly blotted
avidin^HRP and the BIO-phage-binding avidin^HRP were
related (Fig. 1). According to this result, the signal intensity
from 1.0U105 BIO-phages corresponded with that of 4.5U109
molecules of avidin^HRP (molecular weight, V110 kDa).
3.2. Microscopic observation of BIO-phage aggregates
We observed the mixtures of BIO-phages and an avidin^
£uorescein conjugate using £uorescence microscopy. These
mixtures contained many large avidin^BIO-phage aggregates
(Fig. 2a) when the ¢nal concentration of the avidin^£uores-
cein conjugate was v 50 Wg/ml; these large aggregates were
not observed at conjugate concentrations of 6 10 Wg/ml. In a
control experiment, we mixed unbiotinylated phages (2.2U107
cfu) with the avidin^£uorescein conjugate (1 mg/ml) but ob-
served no aggregates (Fig. 2b). We also observed the mixtures
of unbiotinylated phages (8.0U107 cfu/Wl) and anti-M13 anti-
body^£uorescein conjugate (1 mg/ml) and the mixture re-
vealed many aggregates (data not shown).
3.3. Avidin-associated inhibition of the infection of E. coli by
BIO-phages
Various titrations of BIO-phage were added to E. coli
JM109 cultures containing various concentrations of avidin,
and the number of phage-infected bacterial colonies was de-
termined. Avidin reduced the number of BIO-phage-infected
colonies. In contrast, 5 and 10 Wg/ml avidin did not in£uence
infection by unbiotinylated phages (1.5U106 cfu/Wl) (data not
shown). When the solution of BIO-phages was of high titra-
tion (s 7.5U102 cfu/Wl) (Fig. 3a), the colonies began to de-
crease at 2 Wg/ml avidin, became marked at 3 Wg/ml, and was
almost 0 at 5 Wg/ml. Their decrease patterns were similar to
each other. These results indicate that the decreases in the
number of infectious BIO-phages corresponded to the avidin
concentration mainly and not to the ratio of BIO-phages to
avidin molecules at high titration of phage. However, the anti-
body-associated inhibition of phage infection is dependent
upon the antibody concentration (Fig. 4), and the pro¢le of
this inhibition was quite di¡erent from that of avidin^high
titration BIO-phages. Together, these results suggest the avi-
din’s cooperative inhibition of infection by BIO-phages. To
put it concretely, the tetramerization of avidin may cause
marked inhibition of infection by BIO-phages, which may
inhibit their attachment to E. coli due to their aggregation.
When the solution of BIO-phages was of low titration
(9 2.8U102 cfu/Wl), the colonies began to decrease 9 1 Wg/
ml avidin, gradually (Fig. 3b). These ¢ndings were similar to
that of antibody^phages; however, the inhibition was weaker
than that of antibody. These results suggested that monomer
avidin may cause weak inhibition by low titration BIO-phage.
3.4. Time-dependent inhibition of BIO-phage infection by avidin
To investigate the time-dependency of the associated inhi-
Fig. 1. Assessment of the ability of avidin to bind BIO-phages. Ali-
quots of BIO-phages (open circles) and avidin^HRP (solid circles)
were bound to polyvinyldi£uoride membranes, reacted with avidin^
HRP, and made visible by using a chemiluminescent substrate. Rel-
ative intensity was expressed as a ratio with the intensity of
3.5U104 cfu of BIO-phages and is presented as the meansL 1 stan-
dard deviation (bars) of three experiments.
Fig. 2. Confocal microscopy of mixtures of BIO-phages and £uorescein avidin D. a: Mixtures of BIO-phages (6.0U107 cfu) and an avidin^£uo-
rescein conjugate (¢nal concentration, 0.5 mg/ml) showed many large aggregates. b: In a control experiment, we mixed unbiotinylated
M13KO7 phages (2.2U107 cfu) with the avidin^£uorescein conjugate, but no aggregates were observed. Bar, 10 Wm.
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bition of infection, avidin (¢nal concentration, 10 Wg/ml) was
added at various times to E. coli JM109 cultures containing
various titrations of BIO-phages; the titers were determined
1 h after the start of the assay. When avidin was added im-
mediately before the BIO-phages were added, infection was
almost inhibited. Noteworthy inhibition occurred when avidin
was added during the ¢rst 10 min of the assay, but avidin had
lost most of its inhibitory e¡ect on infection by the 20-min
timepoint at each titration (Fig. 5). In contrast, anti-M13 anti-
body (¢nal concentration, 10 Wg/ml) inhibited infection of low
or moderate titration of phages when added at any point
during the ¢rst 45 min after the start of the assay; however,
the inhibition was weak against high titration BIO-phages
(Fig. 5).
4. Discussion
In the present report, we show that BIO-phages were ag-
gregated by avidin and the infection of JM109 cells by BIO-
phages was inhibited by the addition of avidin to the culture
medium in two di¡erent manners. Fluorescence microscopy
revealed many large aggregates in mixtures of BIO-phages
and an avidin^£uorescein conjugate (¢nal concentration, 50
Wg/ml to 1 mg/ml). These large aggregates were not observed
at conjugate concentrations of 6 10 Wg/ml. Inhibition of the
infection could be observed at conjugate concentrations of
6 10 Wg/ml. These results suggest that assembly of several
phage particles (i.e. microaggregates), not formation of large
aggregates, mainly drives inhibition of the infection. Micro-
aggregates may have formed, which might not have been visi-
ble by £uorescence microscopy because of their small size.
Assays of inhibition of phage infection using BIO-phage
and avidin revealed many characteristic ¢ndings. At low con-
centration of BIO-phage, avidin inhibited its infection dose
dependently like that of antibody. However, the inhibition
ability was weaker than that of antibody and was not ob-
served at high concentration of BIO-phage. At high concen-
trations of phages the remarkable inhibition was induced by
v 2 Wg/ml avidin, suggesting that the inhibition was related to
the concentration of avidin and not to the ratio of avidin to
phages. In addition, avidin added before or within 10 min
after the addition of BIO-phages to E. coli cultures markedly
inhibited infection of the cells by the phages. However, the
inhibitory e¡ect of avidin was decreased when it was added to
the phage-containing cultures after 10 min.
The binding avidity of avidin to biotin is very high (Kd,
V10315 M) [10]. Results of a recent protein engineering study
have indicated that monomeric avidin recognizes biotin at a
Kd of V1038 M [11]. In the present study, 1 Wg/ml avidin
corresponded to 1038 M, a concentration that did not lead to
inhibition of infection except for low concentration of phage.
These results suggest that the aggregates we observed are
formed via the following steps: (1) avidin monomers bind
biotinylated capsid proteins; (2) tetramerization of avidin
monomer is induced in a concentration-dependent manner;
(3) tetrameric avidin binds the intercellular BIO-phages; and
(4) aggregates of BIO-phages are formed. Because inhibition
of infection did not occur at 1 Wg/ml avidin at high titration of
phage, not many and simple binding of monomeric avidin
with BIO-phages likely did not in£uence the interaction of
the pIII with the F-pilus and subsequent infection. Thus,
the tetramerization of avidin may cause marked inhibition
of infection by BIO-phages, which may inhibit their attach-
ment to E. coli. In addition, because no clear aggregate could
be observed at the avidin^£uorescein conjugate of 6 10 Wg/ml
on microscopy, large aggregate formation may not be essen-
tial for loss of infectivity.
Our results have demonstrated that both avidin against
BIO-phages and antibodies against phages are agglutogen
Fig. 3. Inhibition of the infection of various concentrations of BIO-
phages into E. coli by avidin. A mixture of 490 Wl of an overnight
culture of E. coli JM109 and 5 Wl of a solution containing various
concentrations of avidin was combined with 5 Wl of a solution con-
taining various concentrations of BIO-phages solutions (a: 9U100
cfu/Wl, open boxes; 1.2U102 cfu/Wl, solid triangles; 7.5U102 cfu/Wl,
open circles; 5.3U103 cfu/Wl, solid boxes; 1.6U105 cfu/Wl, open tri-
angles; 4.3U106 cfu/Wl, solid circles. b: 7.0U100 cfu/Wl, solid boxes;
2.3U101 cfu/Wl, open triangles; 4.5U101 cfu/Wl, solid circles) and in-
cubated for 1 h at 37‡C. After incubation, the solutions were plated
and incubated overnight, after which the bacterial colonies were
counted. Data are presented as the meansL1 standard deviation
(bars) from three experiments.
Fig. 4. Antibody-associated inhibition of infection of E. coli by
BIO-phages. A mixture of 490 Wl of an overnight culture of E. coli
JM109 and 5 Wl of a solution containing various concentrations of
anti-M13 antibody was combined with 5 Wl of a solution containing
M13KO7 phages (2.3U101 cfu/Wl, solid triangles; 6.1U102 cfu/Wl,
open circles; 3.0U104 cfu/Wl, solid boxes; 7.4U105 cfu/Wl, open tri-
angles; 1.0U107 cfu/Wl, solid circles) and incubated for 1 h at 37‡C.
After incubation, the solutions were plated and incubated overnight,
after which the bacterial colonies were counted. Data are presented
as the meansL 1 standard deviation (bars) from three experiments.
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and inhibit the phage infection signi¢cantly. Avidin, however,
inhibits the high titration phage infection in a di¡erent man-
ner from antibody in time-dependency. The antibody activity
against virions most often considered is neutralization includ-
ing aggregation, inhibition of viral entry by inhibition of at-
tachment and inhibition of fusion with the target cell [12^17],
as well as post-entry mechanism, such as interference with
primary and secondary uncoating of the genetic information
of the virus [15]. The decrease of time-dependent inhibition
after 10 min of avidin would indicate that avidin had only a
part of neutralization activity of antibody.
Both additions of avidin before or within 10 min after in-
fection and antibody before or within 45 min of infection
markedly inhibited phage infection. The time-dependent as-
pect of the agglutogen inhibition of infection suggests that
agglutogens may be e¡ective for preventing their infection
of cells. At least pre-existing of agglutogen inhibited virus
infection signi¢cantly. Therefore agglutogen would be an ef-
fective disinfecting and prophylactic agent against virus infec-
tion and expansion from infected cells to uninfected cells.
The development of an agglutogen against a speci¢c virus
and subsequent agglutogen therapy would be an alternative
strategy for the design of antiviral drugs. It might be di⁄cult,
however, to ¢nd and to make agglutogens that combine the
required high speci¢city and avidity. Recently the direct evo-
lution of antibody fragments with femtomolar antigen-bind-
ing a⁄nity has been reported [18] and tetravalent antibody
technologies have been developed for tumor therapy [19^22].
These technologies would provide strong agglutogens against
virus. Ligand-induced multimerization of virus particles by
novel reagents would likely be an e¡ective strategy for the
development of antiviral drugs.
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Fig. 5. Time-sensitivity of inhibition of the infection of E. coli by
BIO-phages. 490 Wl of an overnight culture of E. coli JM109 was
mixed with 5 Wl of a solution containing BIO-phages (1.2U102 cfu/
Wl, solid boxes; 6.3U104 cfu/Wl, solid triangles; 3.2U106 cfu/Wll sol-
id circles) or M13KO7 phages (2.4U102 cfu/Wl, open boxes;
5.2U104 cfu/Wl, open triangles; 2.1U106 cfu/Wl, open circles) and in-
cubated at 37‡C. After various times, 5 Wl of a solution containing
1 mg/ml avidin or 5 Wl of a solution containing 1 mg/ml anti-M13
antibody was added, and the mixture was incubated for a total of
1 h. After incubation, the solutions were plated and incubated over-
night, and then the bacterial colonies were counted. Data are pre-
sented as the meansL 1 standard deviation (bars) from three experi-
ments.
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